A groundbreaking vaccine designed to combat Alzheimer’s disease is set to begin human trials in Adelaide, Australia next week. This marks a significant advancement in the fight against dementia. Developed by Vaxine Pty Ltd in collaboration with the Institute for Molecular Medicine, the vaccine aims to stimulate the immune system to produce antibodies that target and clear toxic beta-amyloid proteins from the brain. The Phase 1 trial will test the safety and immunogenicity of the vaccine in healthy participants aged 40 to 60. This innovative approach could offer a practical and cost-effective preventive measure against Alzheimer’s disease.
Read the full article on TrialSite for more details here : https://www.trialsitenews.com/a/innovative-alzheimers-disease-vaccine-enters-human-trials-in-australia-3d4447ff
